Leanne Dumeny1,2, Orly Vardeny3, Frank Edelmann4,5,6, Burkert Pieske4,5,6,7, Julio D Duarte1,2, Larisa H Cavallari1,2. 1. Center for Pharmacogenomics and Precision Medicine and Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA. 2. Genetics and Genomics, Genetics Institute, University of Florida, Gainesville, Florida, USA. 3. Center for Care Delivery and Outcomes Research, Minneapolis Veteran Affairs Health Care System, Minneapolis, Minnesota, USA. 4. Department of Internal Medicine and Cardiology, Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany. 5. German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. 6. Berlin Institute of Health (BIH), Berlin, Germany. 7. Department of Cardiology, German Heart Center Berlin, Berlin, Germany.
Abstract
STUDY OBJECTIVE: This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants. DESIGN: Post-hoc genetic analysis. DATA SOURCE: Data and samples were derived from the multi-center, randomized, double-blind, placebo-controlled Aldo-DHF trial. PATIENTS: Aldo-DHF participants treated with spironolactone (n = 184) or placebo (n = 178) were included. INTERVENTION: Participants were genotyped for NR3C2 rs5522, NR3C2 rs2070951 and CYP11B2 rs1799998 via pyrosequencing. MEASUREMENTS: In the placebo and spironolactone arms, separate multivariable linear regression analyses were performed for change in E/e' with each single nucleotide polymorphism (SNP), adjusted for age, sex, and baseline E/e'. To discern potential mechanisms of a genotype effect, associated SNPs were further examined for their association with change in blood pressure, circulating procollagen type III N-terminal peptide (PIIINP), and left atrial area. MAIN RESULTS: Carriers of the rs5522 G allele in the placebo arm had a greater increase in E/e' over the 12-month course of the trial compared to noncarriers (β = 1.10; 95% confidence interval [CI]: 0.05-2.16; p = 0.04). No corresponding E/e' worsening by rs5522 genotype was observed in the spironolactone arm. None of the other genotypes were associated with change in E/e'. Compared to noncarriers, rs5522 G carriers also had a greater increase in left atrial area with placebo (β = 0.83; 95% CI: 0.17-1.48; p = 0.01) and a greater reduction in diastolic blood pressure with spironolactone (β = -3.56; 95% CI: -6.73 to -0.39; p = 0.03). Serum PIIINP levels were similar across rs5522 genotypes. CONCLUSIONS: Our results suggest that spironolactone attenuates progression of diastolic dysfunction associated with the NR3C2 rs5522 G allele. Validation of our findings is needed.
STUDY OBJECTIVE: This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants. DESIGN: Post-hoc genetic analysis. DATA SOURCE: Data and samples were derived from the multi-center, randomized, double-blind, placebo-controlled Aldo-DHF trial. PATIENTS: Aldo-DHF participants treated with spironolactone (n = 184) or placebo (n = 178) were included. INTERVENTION: Participants were genotyped for NR3C2 rs5522, NR3C2 rs2070951 and CYP11B2 rs1799998 via pyrosequencing. MEASUREMENTS: In the placebo and spironolactone arms, separate multivariable linear regression analyses were performed for change in E/e' with each single nucleotide polymorphism (SNP), adjusted for age, sex, and baseline E/e'. To discern potential mechanisms of a genotype effect, associated SNPs were further examined for their association with change in blood pressure, circulating procollagen type III N-terminal peptide (PIIINP), and left atrial area. MAIN RESULTS: Carriers of the rs5522 G allele in the placebo arm had a greater increase in E/e' over the 12-month course of the trial compared to noncarriers (β = 1.10; 95% confidence interval [CI]: 0.05-2.16; p = 0.04). No corresponding E/e' worsening by rs5522 genotype was observed in the spironolactone arm. None of the other genotypes were associated with change in E/e'. Compared to noncarriers, rs5522 G carriers also had a greater increase in left atrial area with placebo (β = 0.83; 95% CI: 0.17-1.48; p = 0.01) and a greater reduction in diastolic blood pressure with spironolactone (β = -3.56; 95% CI: -6.73 to -0.39; p = 0.03). Serum PIIINP levels were similar across rs5522 genotypes. CONCLUSIONS: Our results suggest that spironolactone attenuates progression of diastolic dysfunction associated with the NR3C2 rs5522 G allele. Validation of our findings is needed.
Authors: Nienke van Leeuwen; Robert Kumsta; Sonja Entringer; E Ronald de Kloet; Frans G Zitman; Roel H DeRijk; Stefan Wüst Journal: Psychoneuroendocrinology Date: 2009-08-07 Impact factor: 4.905
Authors: Eddy Barasch; John S Gottdiener; Gerard Aurigemma; Dalane W Kitzman; Jing Han; Willem J Kop; Russell P Tracy Journal: Circ Heart Fail Date: 2011-09-07 Impact factor: 8.790
Authors: Neven M Sarhan; Mohamed H Shahin; Nihal M El Rouby; Lamia M El-Wakeel; Mohamed H Solayman; Taimour Langaee; Hazem Khorshid; Mona F Schaalan; Nagwa A Sabri; Larisa H Cavallari Journal: Clin Transl Sci Date: 2019-10-21 Impact factor: 4.689